Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-01-02 @ 9:27 PM
Study NCT ID:
NCT03970967
Status:
TERMINATED
Last Update Posted:
2024-01-18
First Post:
2019-05-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1}}, 'statusModule': {'whyStopped': 'Difficulty in recruiting patients', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2019-08-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-02', 'completionDateStruct': {'date': '2023-11-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-17', 'studyFirstSubmitDate': '2019-05-23', 'studyFirstSubmitQcDate': '2019-05-31', 'lastUpdatePostDateStruct': {'date': '2024-01-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-06-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-11-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Tumor response to DaRT', 'timeFrame': '9-11 weeks post DaRT insertion.', 'description': 'Assessment of the rate of malignant breast tumors response using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).'}, {'measure': 'Adverse Events', 'timeFrame': 'Day 0 - 6 months (+/-14 days)', 'description': 'Assessment of the frequency, severity and causality of acute adverse events related to the DaRT treatment using the Common Terminology and Criteria for adverse events (CTCAE) version 5.0'}], 'secondaryOutcomes': [{'measure': 'Change in tumor volume.', 'timeFrame': '9-11 weeks after DaRT insertion.', 'description': 'Assessment of the reduction in tumor volume SUVmax based on CT/PET - CT measured tumor volume.'}, {'measure': 'DaRT seeds placement', 'timeFrame': 'Day of insertion.', 'description': 'Assessment of the DaRT seed placement by localization of the DaRT seed in the tumor using CT imaging.'}, {'measure': 'Change in quality of life: EORTC-QLQ-C30', 'timeFrame': 'Day 0, 30, 70, 6 months (+/-14 days).', 'description': 'Assessment of patient reported health-related Quality of Life (QoL) outcomes after DaRT treatment, using QoL questionnaires EORTC-QLQ-C30. Scale range in score from 0 (best) to 100(worst).'}, {'measure': 'Progression free survival', 'timeFrame': '6 months (+/-14 days).', 'description': 'Time elapsed from response to disease progression.'}, {'measure': 'Pathological remissions.', 'timeFrame': '12 weeks after DaRT seed insertion.', 'description': 'Assessment of (complete) pathological remissions using histopathology examination'}, {'measure': 'Abscopal effects.', 'timeFrame': '9-11 weeks after DaRT insertion.', 'description': 'Assessment of abscopal effects on existing distant metastases based on PET-CT measured tumor volume.'}, {'measure': 'Change in quality of life: BR23', 'timeFrame': 'Day 0, 30, 70, 6 months (+/-14 days).', 'description': 'Assessment of patient reported health-related Quality of Life (QoL) outcomes after DaRT treatment, using QoL questionnaires BR23. Scale range in score from 0 (best) to 100(worst).'}, {'measure': 'Abscopal effects', 'timeFrame': '9-11 weeks after DaRT insertion.', 'description': 'Assessment of abscopal effects on existing distant metastases based on PET-CT measured SUVmax decrease compared to the primary measurement (the baseline measurement).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Breast carcinoma', 'Metastatic breast cancer', 'Invasive breast cancer', 'Alpha radiation', 'Luminal A', 'Luminal B', 'Triple negative', 'HER2', 'Breast cancer', 'Breast metastases'], 'conditions': ['Breast Carcinoma', 'Metastatic Breast Cancer', 'Invasive Breast Cancer', 'Distant Metastases.Pathology']}, 'descriptionModule': {'briefSummary': 'A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases', 'detailedDescription': 'This will be a prospective, open label, single arm, controlled study, assessing the safety and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive sources \\[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\\] inserted into malignant breast lesions.\n\nThis approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients.\n\nHistopathological confirmed invasive breast tumors with no involvement of skin will be treated using DaRT seeds.\n\nThe primary effectiveness endpoint of the study is the tumor response to DaRT treatment assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) 9-11 weeks after DaRT seed insertion.\n\nSafety will be assessed by the cumulative frequency, severity and causality of acute adverse events related to the DaRT treatment of adverse events (AEs) observed including the follow-up period.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '45 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Subjects with histopathological confirmation of primary (or recurrent) invasive breast carcinoma and distant metastatic disease at diagnosis.\n* Target tumor size ≤ 3.0 cm (T1-2b category);\n* Morphological type: invasive breast cancer\n* Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-, Her2/neu+1), or Triple negative breast carcinoma\n* Measurable disease according to RECIST v1.1.\n* Subjects over 45 years old.\n* Subjects' ECOG Performance Status Scale is \\< 2.\n* Subjects' life expectancy more than 6 months.\n* Platelet count ≥100,000/mm3.\n* International normalized ratio of prothrombin time ≤1.8.\n* Creatinine ≤1.9 mg/dL.\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.\n* Subjects are willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* T4 category with skin involvement.\n* Regional lymph node metastases.\n* Ductal carcinoma in situ.\n* Inflammatory breast carcinoma.\n* Patients with pre-irradiation of the breast.\n* Acute infection disease.\n* The presence of HIV, RW, HbsAg, HCV in the acute stage.\n* Pregnancy or lactation.\n* Serious competing (somatic) diseases incompatible according to the researcher with brachytherapy.\n* Mental illness.\n* Patients undergoing immunosuppressive and/or systemic corticosteroid treatment\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)\n* Subjects not willing to sign an informed consent."}, 'identificationModule': {'nctId': 'NCT03970967', 'briefTitle': 'Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases', 'organization': {'class': 'INDUSTRY', 'fullName': 'Alpha Tau Medical LTD.'}, 'officialTitle': 'A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases', 'orgStudyIdInfo': {'id': 'CTP-BRST-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'DaRT Seeds', 'description': 'Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds', 'interventionNames': ['Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)']}], 'interventions': [{'name': 'Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)', 'type': 'DEVICE', 'description': 'An intratumoral insertion of radioactive sources \\[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.', 'armGroupLabels': ['DaRT Seeds']}]}, 'contactsLocationsModule': {'locations': [{'zip': '249036', 'city': 'Obninsk', 'state': 'Kaluga Oblast', 'country': 'Russia', 'facility': 'A. Tsyb Medical Radiological Research Center', 'geoPoint': {'lat': 55.10993, 'lon': 36.61238}}], 'overallOfficials': [{'name': 'Aleksandr Obukhov', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'A. Tsyb Medical Radiological Research Centre, (A. Tsyb MRRC), Obninsk, Russia'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Alpha Tau Medical LTD.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}